Our previous studies showed that nNOS inhibitors reduced the expression of programmed death-ligand 1 (PD-L1) in the presence of interferon-gamma (IFN-γ), which is a known pro-tumorigenic cytokine stimulating melanoma progression observed in earlier clinical trials and animal studies [16,17,26,27]. This evidence concerns the gene IFNG and melanoma.